SRNE News and Press, Sorrento Therapeutics Inc. From 04/05/21

ACEA’s major assets include: Abivertinib (in oral capsule form), a next generation, dual EGFR mutant and BTK inhibitor (BTKi) with a completed NSCLC registrational/Phase 3 trial, Phase 1 B-cell lymphoma study, and ongoing Phase 2 trials in COVID-19 patients with ARDS, and Pha...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The U.S. currently has three authorized and recommended vaccines, per the Centers for Disease Control and Prevention. And just as the country was roiled by the novel coronavirus, pharmaceutical stocks have had a roller-coa...

Sorrento Therapeutics (SRNE) posts updated positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) for patients suffering from COVID-19-induced acute respiratory distress ((...

All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3 rd COVI-MSC infusion Preparations are ongoing for initiating Phase 2 placebo-controlled study SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, ...

Palm Beach, FL – March 24, 2021 – While the world has reason to become optimistic about seeing a light at the end of the tunnel, due to the development of vaccines to fight and rein in the current global pandemic, more concerns arise if the current vaccines will also tame the ...

Hall of Fame Resort & Entertainment Company (HOFV) +71% after NFT deal.Dolphin Entertainment (DLPN) +66% after NFT deal.Alithya Group (ALYA) +52% on acquisition of R3D ConseilColor Star Technology (CSCW) +41%.Aptose Biosciences (APTO) +39% on Q4 results.Cinedigm C...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unlike other articles I’ve written for InvestorPlace , I’ve got to start this one with a series of caveats. While the theme here is about taking profits off publicly traded companies that have soared on the n...

Sorrento Therapeutics (SRNE) announces that the first patient has been treated in its Phase 1b Amyloid Light Chain ((AL)) Amyloidosis study of STI-6129, an antibody-drug conjugate ((ADC)) which uses STI-5171, a fully human monoclonal antibody (mAb) from Sorrento’s G...

STI-6129 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently bound by a proprietary chemical linker to a duostatin tubulin inhibitor. Amyloid Light Chain (AL) Amyloidosis is an incurable disease with limited treatment options and th...

SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: CEO Roundtable during WuXi Healthcare Forum 2021 Dr. Henry Ji will participate ...